Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Jul 2019
Historique:
received: 27 02 2019
accepted: 01 04 2019
revised: 28 03 2019
pubmed: 5 4 2019
medline: 31 12 2019
entrez: 5 4 2019
Statut: ppublish

Résumé

Circulating and cerebrospinal fluid (CSF) neurofilament light chain (NfL) levels represent a reliable indicator of disease activity and axonal damage in different neuroinflammatory conditions. Recently, high CSF NfL levels have been detected in active autoimmune encephalitis, as opposed to significant lower levels after clinical improvement. The aim of the present study was to evaluate serum and CSF NfL concentration in patients with autoimmune encephalitis and to analyse the association between NfL levels and clinical, MRI, and CSF data. We retrospectively included 25 patients with neurological syndromes associated with autoantibodies to neuronal cell surface antigens and we collected clinical, MRI, CSF, and follow-up data. Using an ultrasensitive method (Simoa, Quanterix), we measured NfL levels in serum and CSF samples of all patients and in 25 sera of healthy controls. Serum NfL levels were higher in all cases, including 20 patients with inflammatory MRI/CSF features and 5 non-inflammatory cases (median 16.9 pg/ml, range 4.5-90) than in controls (median 6.9 pg/ml, range 2.7-12.8; p < 0.001). A correlation between serum and CSF NfL levels was found (r = 0.461, p = 0.023), whereas no significant association was observed between NfL levels and clinical, MRI/CSF inflammatory burden, and antibody type. In the 13 available follow-up samples, correlation between disease activity and NfL values was also observed. In conclusion, NfL levels are significantly increased in the serum of patients with antibody-mediated encephalitis, independently of the MRI/CSF inflammatory profile. These findings support the presence of ongoing axonal damage and suggest the co-occurrence of different mechanisms for neuronal/axonal involvement in antibody-associated CNS syndromes.

Identifiants

pubmed: 30944980
doi: 10.1007/s00415-019-09306-z
pii: 10.1007/s00415-019-09306-z
doi:

Substances chimiques

Biomarkers 0
Neurofilament Proteins 0
neurofilament protein L 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1643-1648

Subventions

Organisme : Ministero della Salute
ID : RF-2011-0234-7955

Références

Lancet Neurol. 2008 Dec;7(12):1091-8
pubmed: 18851928
Acta Neuropathol. 2009 Dec;118(6):737-43
pubmed: 19680671
Brain. 2010 Jun;133(Pt 6):1655-67
pubmed: 20511282
Brain. 2012 May;135(Pt 5):1622-38
pubmed: 22539258
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
Ann Neurol. 2013 Aug;74(2):284-96
pubmed: 23686722
PLoS One. 2013 Sep 20;8(9):e75091
pubmed: 24073237
Front Immunol. 2015 Apr 29;6:206
pubmed: 25972873
Mult Scler. 2016 Oct;22(12):1550-1559
pubmed: 26754800
Eur J Neurol. 2016 Apr;23(4):796-806
pubmed: 26822123
Neurology. 2016 Sep 27;87(13):1329-36
pubmed: 27581216
Neurology. 2017 Feb 28;88(9):826-831
pubmed: 28148632
Eur J Neurol. 2017 May;24(5):703-712
pubmed: 28261960
Physiol Rev. 2017 Apr;97(2):839-887
pubmed: 28298428
J Neuroimmunol. 2017 May 15;306:25-30
pubmed: 28385184
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Lancet Neurol. 2017 Aug;16(8):601-609
pubmed: 28601473
Neurology. 2017 Nov 28;89(22):2230-2237
pubmed: 29079686
Mult Scler J Exp Transl Clin. 2017 Nov 22;3(4):2055217317743098
pubmed: 29204292
Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422
pubmed: 29209636
J Neurol. 2018 Mar;265(3):510-521
pubmed: 29322259
N Engl J Med. 2018 Mar 1;378(9):840-851
pubmed: 29490181
Neurology. 2018 Apr 3;90(14):e1231-e1239
pubmed: 29514947
Mult Scler. 2019 Apr;25(5):678-686
pubmed: 29542376
Brain. 2018 Aug 1;141(8):2382-2391
pubmed: 29860296
Neuropathol Appl Neurobiol. 2019 Apr;45(3):291-304
pubmed: 29908069
Parkinsonism Relat Disord. 2018 Nov;56:98-101
pubmed: 29937097

Auteurs

Sara Mariotto (S)

Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Policlinico GB Rossi, P.le LA Scuro 10, 37135, Verona, Italy. sara.mariotto@gmail.com.

Alberto Gajofatto (A)

Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Policlinico GB Rossi, P.le LA Scuro 10, 37135, Verona, Italy.

Luigi Zuliani (L)

Neurology Unit, AULSS8 Berica, San Bortolo Hospital, Vicenza, Italy.

Marco Zoccarato (M)

Neurology Unit, Ulss 6 Euganea, Padua, Italy.

Matteo Gastaldi (M)

Neuroimmunology Laboratory, IRCCS Mondino Foundation, Pavia, Italy.

Diego Franciotta (D)

Neuroimmunology Laboratory, IRCCS Mondino Foundation, Pavia, Italy.

Gaetano Cantalupo (G)

Child Neuropsychiatry, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, Italy.

Francesca Piardi (F)

Child Neurology, Sacro Cuore Hospital, Verona, Italy.

Alberto Polo (A)

Neurology Unit, Mater Salutis Hospital, Legnago, Verona, Italy.

Daniela Alberti (D)

Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Policlinico GB Rossi, P.le LA Scuro 10, 37135, Verona, Italy.

Stefano Sartori (S)

Paediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, University Hospital of Padua, Padua, Italy.

Gianluigi Zanusso (G)

Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Policlinico GB Rossi, P.le LA Scuro 10, 37135, Verona, Italy.

Luigi Agrò (L)

Neurology Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.

Rita Demurtas (R)

Neurology Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.

GianPietro Sechi (G)

Neurology Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.

Elia Sechi (E)

Neurology Unit, Department of Clinical and Experimental Medicine, University of Sassari, Sassari, Italy.

Salvatore Monaco (S)

Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Policlinico GB Rossi, P.le LA Scuro 10, 37135, Verona, Italy.

Sergio Ferrari (S)

Neurology Unit, Department of Neuroscience, Biomedicine and Movement Sciences, University of Verona, Policlinico GB Rossi, P.le LA Scuro 10, 37135, Verona, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH